Your browser doesn't support javascript.
loading
Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
Thieringer, Rolf; Hermanowski-Vosatka, Anne.
Affiliation
  • Thieringer R; Department of Cardiovascular Diseases, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA. rolf_thieringer2@merck.com
Expert Rev Cardiovasc Ther ; 3(5): 911-24, 2005 Sep.
Article in En | MEDLINE | ID: mdl-16181035
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Database: MEDLINE Main subject: Metabolic Syndrome / 11-beta-Hydroxysteroid Dehydrogenase Type 1 / Glucocorticoids Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Expert Rev Cardiovasc Ther Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Year: 2005 Type: Article Affiliation country: United States
Search on Google
Add to My VHL
Print
XML
PubMed Links

Database: MEDLINE Main subject: Metabolic Syndrome / 11-beta-Hydroxysteroid Dehydrogenase Type 1 / Glucocorticoids Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Expert Rev Cardiovasc Ther Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Year: 2005 Type: Article Affiliation country: United States